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(57) ABSTRACT 
This invention provides materials and methods to manipu 
late the plant genome at the level of single plant cells in 
culture resulting in the ability to assign metabolic function 
ality to plant genes involved in the production of biologi 
cally active molecules and to create a means of product 
discovery based on the biosynthetic capacity of plants. The 
materials to create an activation mutagenesis include incor 
poration of enhancer sequences from a plant viral promoter 
at random places in the plant genome via Agrobacterium 
mediated DNA transfer (T-DNA). The usefulness is that 
genes in the immediate vicinity of the incorporation were 
activated which allows for immediate screening of the 
mutageniZed plant cells. Additionally, the usefulness 
includes relevant areas of the genome were ?anked by the 
inserted T-DNA which allows recovery of this area by 
standard molecular biology techniques. The method 
includes a procedure for screening large numbers of 
mutageniZed plant cell cultures for activation of a relevant 
gene on the basis of the desired protein product on the basis 
of radioligand binding displacement assay. 
12 Claims, 11 Drawing Sheets 
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METHODS TO IDENTIFY PLANT 
METABOLITES 
CROSS REFERENCE TO RELATED 
APPLICATION 
This application claims bene?t of priority from US. 
Provisional Application Ser. No. 60,267,438, ?led Feb. 9, 
2001. 
BACKGROUND OF THE INVENTION 
Plants are sources of drugs and other useful materials. 
These materials are the products of plant metabolism, Which 
is the total collection of biochemical pathWays Within a 
plant. Genes encode the enZymes that function in plant 
metabolic pathWays and regulatory genes, in turn, control 
the activity of metabolic pathWays by directing the expres 
sion of entire sets of enZyme-encoding genes speci?c to a 
given pathWay. It folloWs that methods to identify any genes 
that govern the production of such plant metabolites are 
critical to enable the manipulation of pathWays for elevating 
product yield and for increasing the diversity of these 
substances. The present invention provides methods to iden 
tify, in a relatively ef?cient and reliable manner, plant 
genetic material required for production of metabolites 
Which Would ordinarily be dif?cult to identify. The invention 
is the realiZation of the successful merging of tWo distinct 
methodologies: activation-tagging mutagenesis and high 
throughput screening. The present unique combination of 
these methodologies results in the ability to assign metabolic 
functionality to plant genes involved in the production of 
biologically active molecules and to create a means of 
compound discovery based on the genetic capabilities of a 
plant or group of plants. 
This invention is therefore based on the folloWing tech 
nical developments: 1) methodology Which enables propa 
gation and maintenance of mutageniZed “microcallus” mate 
rial in a “library” format in such a Way as to permit large 
scale screening; 2) procedures to nondestructively sample 
the microcallus; 3) methodology to screen the microcallus 
sample in a miniaturiZed high throughput pharmacological 
screen. 
Therefore, the invention is in the ?eld of plant molecular 
biology, in particular, genetic methods for production and 
identi?cation of useful compounds. 
Identi?cation of plant genes via activation mutagenesis 
has been used With success previous to the present invention. 
This technique involves incorporation of enhancer 
sequences from a plant viral promoter at random places into 
the plant genome viaAgrobacterium mediated T-DNA trans 
fer. When applied to single plant cells in culture, the 
resulting mutants are identi?ed by positive selection, and the 
gene(s) in the vicinity of the T-DNA insert is cloned. 
HoWever, elucidation of the effects of mutations in regula 
tory regions, or doWnstream effects from a mutageniZed 
gene, are very difficult in cases Where no positive selection 
schemes can be employed. Even With classical activation 
mutagenesis methods, Walden et al. conclude “this process 
is involved, labor-intensive and can only be effectively 
carried out With relatively limited numbers of segregating 
individuals.” Walden et al., Methods in Cell Biology, 
49:455—469 (1995). 
High-throughput screening has also been utiliZed in the 
pharmaceutical ?eld. 
Citation of the above document is not intended as an 
admission that any of the foregoing is pertinent prior art. All 
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2 
statements as to the date or representation as to the contents 
of these documents is based on subjective characteriZation 
of information available to the applicant and does not 
constitute any admission as to the accuracy of the dates or 
contents of these documents. 
SUMMARY OF THE INVENTION 
The present invention provides a method for identifying 
plant genetic material Whose actions cause increased pro 
duction of a metabolite or metabolites of interest in plant 
cells, said method comprising causing random integration 
into the plant genome in plant protoplasts of at least one 
enhancer-containing T-DNA genetic element harboring 
sequences to enable bacterial replication and selection; 
groWing said protoplasts to the stage of callus cultures; 
sampling said callus cultures in such a manner as to retain 
viability of said clonal cultures; analyZing said samples to 
identify the callus cultures producing metabolite or metabo 
lites of interest; and isolating and identifying the plant 
genetic material, the action of Which has been stimulated by 
the enhancer-containing T-DNA genetic element in the 
sampled, identi?ed callus cultures. 
Preferred is a method Wherein the plant genetic material, 
Which is identi?ed, is a plant gene Whose action causes a 
plant cell to produce an increased amount of a metabolite or 
metabolites of interest. More preferred is a method Wherein 
the plant genetic material, Which is identi?ed, is a regulatory 
gene. Also preferred is a method Wherein the analysis of 
callus cultures detects the production of metabolites of 
interest having pharmacological properties. Most preferred 
is a method Wherein said metabolites are detected via at least 
one radioligand displacement assay. 
Methods of the present invention, Which comprises the 
further step of propagating at least one callus, culture 
producing said metabolite or metabolites. Most preferred are 
methods, Which involve a tobacco plant. 
Most preferred are methods Wherein said enhancer 
sequence is a plant viral enhancer sequence. 
Most preferred are methods Wherein said enhancer 
sequence is delivered to the plant via Agrobacterium tume 
faciens. 
Preferred are methods Wherein said radioligand is a 
nicotinic acetylcholine agonist or a nicotinic acetylcholine 
antagonist. Most preferred is the radioligand [3H]-epibati 
dine or [3H]-methyllycaconitine. 
The present invention provides a method for identifying 
plant genetic material Whose actions cause increased pro 
duction of a metabolite or metabolites of interest in plant 
cells, said method comprising co-cultivating plant proto 
plasts With Agrobacterium cells harboring an activation 
tagging vector; embedding the plant protoplasts in agarose; 
transferring the embedded protoplasts to a larger surface 
area to alloW further groWth; eXcising individual, clonal calli 
resulting from said groWth; partially macerating individual 
samples of tissue from said calli in multi-Welled microtiter 
plates to establish a sample clonal library; removing super 
natant liquid fractions from said macerated samples; sub 
jecting said supernatant fractions to radioligand displace 
ment assays to determine if metabolites in the liquid 
supernatant displace the radioligand; adding groWth medium 
to remaining tissues in the microtiter plate; and isolating and 
identifying the plant genetic material, the action of Which 
has been stimulated by the action of the activation-tagging 
vector, from the callus cultures Which generated ligand 
displacement in the radioligand displacement assay. 
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The present invention provides methods for detecting a 
metabolite in a plant comprising: causing integration of at 
least one enhancer-containing T-DNA in a plant protoplast; 
groWing said protoplast to the stage of callus culture; 
sampling said callus in such a manner so as to retain viability 
of said callus culture; and detecting a metabolite of interest. 
Those methods Wherein said metabolite is detected via at 
least one radioligand displacement assay are preferred. More 
preferred are methods as described Which further comprise 
the step of continuous propagation of at least one stably 
transformed culture. 
In the present invention, methods Wherein the plant is a 
tobacco plant are preferred. Those methods Wherein said 
enhancer sequence is a plant viral enhancer sequence are 
also preferred. Most preferred are those methods, Which 
utiliZe a viral enchancer sequence, delivered via Agrobac 
terium tumefaciens. 
When the detection means is a radioligand displacement 
assay, methods Wherein said radioligand is a nicotinic ace 
tylcholine agonist or a nicotinic acetylcholine antagonist are 
preferred. In particular, those methods Wherein said radio 
ligand is [3H]-epibatidine are more preferred. 
Also provided are methods for detecting a metabolite in a 
plant comprising: co-cultivating protoplasts With Agrobac 
terial cells harboring an activation tagging vector; embed 
ding the protoplasts in agarose; transferring protoplasts to a 
larger surface area to alloW further groWth; excising indi 
vidual calli tissue; partially macerating individual calli tissue 
in a multi-Welled microtitre plate; establishing a viable 
callus library; removing liquid supernatant; adding groWth 
medium to tissues remaining in the microtitre plate; and 
conducting radioligand displacement assay to determine if a 
metabolite displaces the radioligand. 
For the purposes of the present invention, the term “a” or 
“an” entity refers to one or more of that entity; for example, 
“a metabolite” or “a radioligand” or “an assay” refers to one 
or more of those compounds or at least one compound. As 
such, the terms “a” (or an”), “one or more” and “at least one” 
can be used interchangeably herein. It is also to be noted that 
the terms “comprising”, “including”, and “having” can be 
used interchangeably. Furthermore, a compound “selected 
from the group consisting of” refers to one or more of the 
compounds in the list that folloWs, including mixtures (i.e. 
combinations) of tWo or more of the compounds. According 
to the present invention, an isolated or biologically pure, 
protein or nucleic acid molecule is a compound that has been 
removed from its natural milieu. As such, “isolated” and 
“biologically pure” do not necessarily re?ect the extent to 
Which the compound has been puri?ed. An isolated com 
pound of the present invention can be obtained from its 
natural source, can be produced using molecular biology 
techniques or can be produced by chemical synthesis. 
These and other objects of the invention Will be more fully 
understood from the folloWing description of the invention, 
the referenced draWings attached hereto and the claims 
appended hereto. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The present invention Will become more fully understood 
from the detailed description given herein beloW, and the 
accompanying draWing, Which is given by Way of illustra 
tion only, and thus is not limitative of the present invention. 
FIG. 1 shoWs a protoplast isolation and transformation 
?owchart. 
FIGS. 2A—B. FIG. 2A shoWs a photograph taken through 
a bright ?eld microscope (40>< magni?cation) of freshly 
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4 
isolated protoplasts from tobacco leaves tWo days after 
isolation. At seven days the protoplasts are co-cultivated 
With Agrobacterium tumefacians (GV3101) to conduct 
transformation resulting in the insertion of the activation 
tagging T-DNA. FIG. 2B shoWs a photograph of a cluster of 
clonal cells after several steps of incubation, Washing, 
antibiotic selection and embedding of the multiplied proto 
plasts. The clusters of clonal cells become macroscopic 
(referred to as “microcalli”) as shoWn in the dish in the right 
of the ?gure. Diameter of the petri dish shoWn is 150 mm. 
FIGS. 3A—B. FIG. 3A shoWs a photograph of a plate of 
surface-embedded calli after propagation for approximately 
?ve Weeks (compare to microcalli in FIG. 2). This is an 
example of the type of density used of mutageniZed material 
used for sampling to conduct the pharmacological assay. 
FIG. 3B shoWs a photograph of a standard 48-well plate 
shoWing regroWth of the mutageniZed callus tissue after 
sampling and extract preparation Which took place in the 
same Wells approximately three Weeks previously. 
FIG. 4 shoWs a photograph of an “activation-tagging 
mutagenesis” (ATM) library that harbors over 1300 indi 
vidual mutant clones. This illustrates the Workability of 
establishing a viable “master” library developed using the 
methods described herein. 
FIGS. 5A—B. FIG. 5A shoWs a photograph of an indi 
vidual screen-positive callus clone that had been physically 
divided and propagated as approximately 20 clonal pieces of 
separate callus tissue. This is used for veri?cation of the 
pharmacological phenotype, as each “daughter” individual 
is expected to have the same displacement activity as the 
“parental” tissue. FIG. 5B shoWs that such pieces are also 
used for plant regeneration from the calli (right half). 
FIG. 6 shoWs a photograph of plants groWing on synthetic 
media in Magenta boxes that had been regenerated from 
calli scored as positive in the screen. 
FIG. 7 shoWs a graph of displacement data of a population 
of mutant (“ATM”) and Wild type (“no ATM”) using 3H-epi 
batidine as the ligand in the pharmacological screen. Non 
mutated samples shoW average displacement of approxi 
mately 3% Whereas the ATM population indicates tWo 
individuals With greater than 30 and 70% displacement 
activity, respectively. Note the log scale on the X-axis. These 
data are typical for many thousands of assays run to date. 
FIG. 8 shoWs a summary of activities of positive mutant 
lines and Wild-type controls expressed in terms of “nicotine 
displacement activity” or approximately equivalent to a 
given concentration of nicotine in the displacement assay. 
Note log scale on the Y-axis. The upper clone represents 
activity 10,000 times higher than that found in Wild-type 
calli. This line is no. 7309. The line With the loWest activity 
(and regenerated and analyZed at the Whole plant level) is 
no. 1402. 
FIGS. 9A—D. FIGS. 9A and 9B shoW initial activity 
characteriZation by displacement activity of line no. 1402 
callus (See discussion text). The pure anabasine alkaoid and 
pure nicotine alkaloid are used here to standardiZe the 
system. FIGS. 9C and 9D shoW characteriZation of crude 
callus extracts performed in the same Way as that in A. This 
difference in the shape of the pro?les indicates that the 
activity in the 1402 extract is distinct from Wildtype and is 
most likely a compound other than nicotine. 
FIG. 10 shoWs a summary of the molecular characteriZa 
tion of cell line 1402. 
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DETAILED DESCRIPTION OF THE 
INVENTION 
The present invention provides a method for identifying 
plant genetic material Whose actions cause increased pro 
duction of a metabolite or metabolites of interest in plant 
cells, said method comprising causing random or directed 
integration into the plant genome in plant protoplasts of at 
least one enhancer-containing T-DNA genetic element har 
boring sequences to enable bacterial replication and selec 
tion; groWing said protoplasts to the stage of callus cultures; 
sampling said callus cultures in such a manner as to retain 
viability of said clonal cultures; analyZing said samples to 
identify the callus cultures producing metabolite or metabo 
lites of interest; and isolating and identifying the plant 
genetic material, the action of Which has been stimulated by 
the enhancer-containing T-DNA genetic element in the 
sampled, identi?ed callus cultures. 
Preferred is a method Wherein the plant genetic material, 
Which is identi?ed, is a plant gene Whose action causes a 
plant cell to produce an increased amount of a metabolite or 
metabolites of interest. More preferred is a method Wherein 
the plant genetic material, Which is identi?ed, is a regulatory 
gene. Also preferred is a method Wherein the analysis of 
callus cultures detects the production of metabolites of 
interest having pharmacological properties. Most preferred 
is a method Wherein said metabolites are detected via at least 
one radioligand displacement assay. 
Methods of the present invention may also comprise the 
further step of propagating at least one callus culture pro 
ducing said metabolite or metabolites. Most preferred are 
methods, Which involve a tobacco plant and wherein said 
enhancer sequence is a plant viral enhancer sequence. 
Most preferred are methods Wherein said enhancer 
sequence is delivered to the plant via Agrobacterium tume 
faciens. 
Preferred are methods Wherein said radioligand is a 
nicotinic acetylcholine agonist or a nicotinic acetylcholine 
antagonist. Most preferred is the radioligand [3H]-epibati 
dine or [3H]-methyllycaconitine. 
In a preferred embodiment, the present invention provides 
a method for identifying plant genetic material Whose 
actions cause increased production of a metabolite or 
metabolites of interest in plant cells, said method comprising 
co-cultivating plant protoplasts With Agrobacterium cells 
harboring an activation-tagging vector; embedding the plant 
protoplasts in agarose; transferring the embedded proto 
plasts to a larger surface area to alloW further groWth; 
excising individual, clonal calli resulting from said groWth; 
partially macerating individual samples of tissue from said 
calli in multi-Welled microtiter plates to establish a sample 
clonal library; removing supernatant liquid fractions from 
said macerated samples; subjecting said supernatant frac 
tions to radioligand displacement assays to determine if 
metabolites in the liquid supernatant displace the radioli 
gand; adding groWth medium to remaining tissues in the 
microtiter plate; and isolating and identifying the plant 
genetic material, the action of Which has been stimulated by 
the action of the activation-tagging vector, from the callus 
cultures Which generated ligand displacement in the radio 
ligand displacement assay. 
The present invention provides methods for detecting a 
metabolite in a plant comprising: causing integration of at 
least one enhancer-containing T-DNA in a plant protoplast; 
groWing said protoplast to the stage of callus culture; 
sampling said callus in such a manner so as to retain viability 
of said callus culture; and detecting a metabolite of interest 
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in the event that the metabolite of interest is present. Those 
methods Wherein said metabolite is detected via at least one 
radioligand displacement assay are preferred. More pre 
ferred are methods as described Which further comprise the 
step of propagating at least one daughter culture. 
In the present invention, methods Wherein the plant is a 
tobacco plant are preferred. Those methods Wherein said 
enhancer sequence is a plant viral enhancer sequence are 
also preferred. Most preferred are those methods, Which 
utiliZe a viral enhancer sequence, delivered via Agrobacte 
rium tumefaciens. 
When the detection means is a radioligand displacement 
assay, methods Wherein said radioligand is a nicotinic ace 
tylcholine agonist or a nicotinic acetylcholine antagonist are 
preferred. In particular, those methods Wherein said radio 
ligand is [3H]-epibatidine are more preferred. 
Also provided are methods for detecting a metabolite in a 
plant comprising: co-cultivation of protoplasts With Agro 
bacterial cells harboring an activation-tagging vector; 
embedding the protoplasts in agarose; transferring proto 
plasts to a larger surface area to alloW further groWth; 
excising individual calli tissue; partially macerating indi 
vidual calli tissue in multi-Welled microtitre plate; removing 
liquid supernatant; conducting radioligand displacement 
assay to determine if a metabolite displaces the radioligand; 
and adding groWth medium to tissues remaining in the 
microtitre plate. 
Other methods of transformation include: biolistic bom 
bardment and polyethylene glycol-mediated DNA uptake. 
Plant cells may also be transformed With other sequences 
With the ability to cause the activation of genes such as 
enhancer sequences from different promoters and sequences 
encoding transcription factors that can function to activate 
gene expression or from the introduction of populations of 
genes in order to determine their impact on metabolite 
production. 
The supernatant may be assayed for products of second 
ary metabolism With radiolabelled ligand binding assays. 
Preferred ligands are acetylcholine agonists and antagonists. 
More preferred are 3H-methyllycaconitine, 3H-spermidine. 
Most preferred is 3H-epibatidine. 
Preferred enhancer sequences include tissue-speci?c pro 
moter enhancers and temporal-speci?c promoter enhancers. 
Most preferred is a constitutive plant viral promoter active 
in plant cells and undifferentiated callus tissue. 
Enhancer sequences may be contained Within vectors 
enabling the transfer of said sequences into the plant 
genome. 
The term “antagonist” is intended to refer to that Which is 
understood in the art. In general, the term refers to a 
substance that interferes With receptor function. Antagonists 
are of tWo types: competitive and non-competitive. A com 
petitive antagonist (or competitive blocker) competes With 
the naturally occurring ligand for the same binding site. In 
the case of acetylcholine, an example of such an antagonist 
is bungarotoxin. A non-competitive antagonist or blocker 
inactivates the functioning of the receptor by binding to a 
site other than the acetylcholine-binding site. 
Speci?cally, the radiolabeled ligand may bind nicotinic 
acetylcholine receptors. The preferred radiolabeled ligand is 
[3H]-epibatidine, a nicotinic cholinergic receptor agonist. 
Cholinergic receptors play an important role in the func 
tioning of muscles, organs and generally in the central 
nervous system. There are also complex interactions 
betWeen cholinergic receptors and the function of receptors 
of other neurotransmitters such as dopamine, serotonin and 
catecholamines. 
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Acetylcholine (ACh) serves as the neurotransmitter at all 
autonomic ganglia, at the postganglionic parasympathetic 
nerve endings, and at the postganglionic sympathetic nerve 
endings innervating the eccrine sWeat glands. Different 
receptors for ACh exist on the postganglionic neurons Within 
the autonomic ganglia and at the postjunctional autonomic 
effector sites. Those Within the autonomic ganglia and 
adrenal medulla are stimulated predominantly by nicotine 
and are knoWn as nicotinic receptors. Those on autonomic 
effector cells are stimulated primarily by the alkaloid mus 
carine and are knoWn as muscarinic receptors. 
The nicotinic receptors of autonomic ganglia and skeletal 
muscle are not homogenous because they can be blocked by 
different antagonists. For example, d-tubocurarine effec 
tively blocks nicotinic response in skeletal muscle, Whereas 
hexamethonium and mecamylamine are more effective in 
blocking nicotinic responses in autonomic ganglia. The 
nicotinic cholinergic receptors are named the NM and NN 
receptors, respectively. 
Acetylcholine receptors at any or all of the above men 
tioned locations may be assayed by radiolabeled ligand 
binding assays in the present invention. 
EXAMPLES 
The folloWing examples illustrate the present invention 
Without, hoWever, limiting it. It is to be noted that the 
Examples include a number of molecular biology, microbi 
ology and biochemistry techniques considered to be knoWn 
to those skilled in the art. Disclosure of such techniques can 
be found, for example, in Sambrook et al., ibid., and related 
references. 
Example 1 
Leaf Protoplast Preparation 
GroWing Conditions: Tobacco plants (Nicotiana tabacum 
SR1) Were groWn in sterile culture on MS media (One liter 
contains: 4.3 g MS basal salt mixture (Sigma), 0.5 g MES 
(2-[N-Morpholino]ethanesulfonic acid) (Sigma) for buffer 
ing, 10 g sucrose. The pH Was adjusted to 5.8 With KOH. 
Media Was solidi?ed by adding Phytagel (Sigma) to 0.2%. 
SteriliZation Was by autoclaving in Magenta boxes. Magenta 
boxes contained lids With a vent provided by a 2 cm 
diameter hole covered With a single 0.45 pm pore siZe ?lter 
disc (Type HA, Millipore) and tWo pieces of “Micropore” 
surgical tape (3 M). Plants groWn for four to ?ve Weeks at 
24° C. under approximately 110 pmol m_2s_1 light intensity 
Were used as a source of leaf material. 
Leaf Preparation Procedure: Under sterile conditions, leaf 
tissue Was removed from the plants and cut into approxi 
mately 1 cm2 pieces using a sharp scalpel or raZor blade. 
Approximately 5 g of leaf material Was added to 20 ml 
?lter-steriliZed enZyme solution (1.5% cellulase, 0.5% pec 
tinase, (Sigma)) in K3 plant culture media. K3 media 
contains 10 ml per liter of the folloWing stock solutions: 
NaHZPO4 (3 g/200 ml); CaCl2 (18 g/200 ml); (NH4)2SO4 
(2.7 g/200 ml); MgSO4 (5 g/200 ml); KNO3, (5 g/200 ml); 
NH4NO3 (2.7 g/200 ml). Added directly to one liter of K3 
media Was inositol, 100 mg; xylose, 250 mg; and MES 
buffer, 2.0 g. In addition, K3 media also contained 10 ml per 
liter of a micronutrients solution and 1.0 ml per liter of a 
vitamin solution. The micronutrient solution Was prepared 
by dissolving the folloWing into one liter H2O: H3BO3, 6.2 
g; MnSO4~4H2O, 22.3 g; ZnSO4~7H2O, 10.6 g; KI, 0.88 g; 
NaMoO4~2H2O, 0.25 g; CuSO4~5H2O, 0.025 g; and 
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CoCl2-6H2O, 0.025 g. The vitamin stock solution Was made 
by dissolving the folloWing in 200 ml H2O: glycine, 400 mg; 
nicotinic acid, 400 mg; pyridoxin-HCl, 400 mg; thiamin 
HCl, 20 mg. 5.0 ml of an Fe-EDTA solution Was added from 
a stock, prepared by dissolving 5.57 g FeSO4~7H2O and 7.45 
g NaZEDTA. To prepare K3 containing 0.4 M sucrose, 
136.92 g sucrose Was added. 0.1 M sucrose K3 media 
contains 34.23 g sucrose. 
Protoplast Isolation: Leaves Were digested overnight (no 
more than 19 h) by incubation at 26° C. in the dark. The 
folloWing day, 250 ml beakers Were mixed for 10 min on an 
orbital shaker (approximately 40 rpm), and the solution Was 
passed through a 105 pm mesh sieve by pouring through a 
?ltration apparatus. This Was divided into 17><100 mm 
sterile plastic centrifuge tubes, Which Were then centrifuged 
at 2000 rpm in a sWinging bucket rotor for 6 minutes at room 
temperature. FolloWing the centrifugation, protoplasts, 
Which ?oat at the top of the media in the centrifuge tube, 
Were removed from the pelleted debris by aspirating the 
loWer contents of the tube. Protoplasts Were Washed by 
addition of 0.4 M K3 media and recentrifuged. The proto 
plasts from these Were pooled into one or tWo single screW 
cap sterile tubes. After adjusting protoplast cell density, cells 
Were further incubated as 10 ml cultures in standard (60 mm) 
petri dishes. Dishes Were Wrapped With para?lm for incu 
bation at 26° C. in the dark for tWo days. 
Example 2 
Activation-Tagging Mutagenesis: Protoplast 
Transformation 
Materials: Agrobacterium tumefaciens strain GV3101, is 
described in KoncZ and Schell, Mol Gen Genet 
204:383—396. 1986, Which is incorporated herein by refer 
ence in its entirety. The plasmid pPCVICEn4HPT contain 
ing the T-DNA tag Was used. It Was made as described in 
FritZe and Walden, Methods in Molecular Biology 
44:281—294. 1995 and in Walden, FritZe and Harling, Meth 
ods in Cell Biology 49:455—469. 1995, Which references are 
incorporated by reference herein in their entirety. 
pPCVICEn4HPT is derived from the pPCV vector (KoncZ 
and Schell, Mol Gen. Genet 213:285—290, 1986.) in Which 
the T-DNA contains four tandemly repeated enhancer ele 
ments derived from the 35S RNA promoter of the Cauli 
?ower mosaic virus, a hygromycin resistance marker for 
protoplast and plant selection and an E. coli plasmid 
sequence that contains an E. coli origin of replication and an 
ampicillin resistance gene. 
Procedure: Transformation With the activator T-DNA tag 
Was performed by co-cultivation With Agrobacterium tume 
faciens harboring the T-DNA tagging element (strain 
GV3101, plasmid pPCVICEn4HPT). Freshly groWn bacte 
rial cells Were added directly to six to eight day-old proto 
plast cultures in a ratio of 100:1 bacteria to protoplast cells. 
Co-cultivation Was conducted at 26° C. in the dark for 48 hr. 
At the end of the incubation period, protoplasts Were Washed 
three times in W5 media by centrifugation in a sWing-out 
rotor at room temperature. W5 media contained NaCl, 9.0 
g/liter; CaCl2~2H2O, 18.38 g/liter; KCl, 0.373 g/liter; and 
glucose, 0.90 g/liter. The pH Was adjusted to 5 .6—6.0, With 
HCl. The medium Was steriliZed by autoclavation. Proto 
plasts Were then resuspended in 0.4 M K3 media to produce 
a ?nal concentration of 106 protoplasts per ml. One ml of 
protoplast suspension Was transferred to a standard (100 
mm) petri dish and cultured in a ?nal volume of 10 ml of 0.4 
M K3 media containing antibiotic selection against Agro 
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bacterium cells (cefotaxime 500 pig/ml) as well as the 
presence of hormones to maintain cells in a dedifferentiated 
state (auxin (NAA) 1.0 pig/ml and cytokinin (kinetin 0.2 
pig/ml). Hygromycin (15 pig/ml) was also added to the 
incubation media to select for the protoplasts transformed 
with the activation-tagging vector. 
Example 3 
Propagation of Protoplasts and Calli 
Culturing of Protoplasts: Transformed cells were embed 
ded in 0.3% low gelling temperature agarose in 100 mm 
petri dishes. K4 media was then added to the petri dishes 
containing the soft agarose embedded microcalli. Following 
protoplast embedding, the K4 media was reduced in osmo 
larity in 0.1 M increments, (starting at 0.4 M sucrose, ~580 
mOsm) on a weekly basis by changing the liquid phase 
media over the soft agarose embedded cells. “K4” media 
contains 10 ml per liter of the following stock solutions: 
NaHZPO4 (3 g/200 ml); CaCl2 (18 g/200 ml); KCl (58.8 
g/200 ml); glutamine (17.54 g/200 ml); asparagine (5.32 
g/200 ml); arginine (3.52 g/200 ml); (NH 4)2SO 4 (2.7 g/200 
ml); MgSO4 (5 g/200 ml). Added directly to one liter of K4 
media is inositol, 100 mg; xylose, 250 mg, and MES buffer, 
2.0 g. In addition, K4 media also contains 10 ml per liter of 
a micronutrients solution and 1.0 ml per liter of a vitamin 
solution with the same composition as that used for the K3 
media as well as 5.0 ml per liter of a Fe-EDTA solution and 
sucrose to 0.4 or 0.1 M. 
Transfer to Larger Areas for Additional Growth: Once 
microcalli were established (usually four to ?ve weeks), 
they were released from the agarose by gentle maceration 
and dilution. Microcalli were further cultured by “surface 
plating” the transformed tissue onto 0.1 M K4 media solidi 
?ed with 0.8% agar in 150 mm dishes. The released micro 
calli were “re-embedded” in low gelling-temperature agar 
ose and plated to the surface of solidi?ed K4 media agar 
plates. This results in a 2 mm thick monolayer of embedded 
microcalli on the plate such that further growth forms an 
upward protrusion of the calli large enough for physical 
sampling. Dilutions were empirically made to adjust the 
number of individual microcalli on each dish to densities 
sufficient to enable continued growth of the microcalli up to 
the stage of sampling. 
Example 4 
Nondestructive Sampling and Library 
Establishment 
The three steps of sampling, establishment of a viable 
working library and extract preparation of surface-grown 
macrocalli are combined into a single process to maximiZe 
throughput. Surface-embedded microcalli grown to siZes 
ranging from approximately 0.5 cm to 1.5 cm (“macrocalli”) 
are deemed sufficient for sampling and establishing the 
master library. Under sterile conditions, petri dishes con 
taining the surface-grown macrocalli are opened and mac 
rocalli are individually sampled using ring forceps (4.8 mm 
inner ring diameter, Fine Science Tools, Inc. Foster City, 
Calif.). This ring siZe enables a section of tissue weighing 
approximately 50 mg to be sampled. The removed tissue 
section is placed into the numbered well of a 48-well 
microtiter plate containing 0.4 ml fresh K4 media including 
required growth regulators. Once the 48-well dishes are 
loaded, a maceration pestle, custom made of DelrinTM plas 
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tic (12 cm in length><1-cm dia.) with the maceration end 
machined to a semi-circle (one-half of the 1-cm circular end) 
is used to partially macerate the tissue in the well of the 
plate. Partial maceration is conducted to break open a 
suf?cient proportion of the cells within the 50 mg piece of 
callus tissue to release the cellular contents for analysis and 
to maintain an amount of this tissue (generally about 1/3 of 
each callus section) in the well to enable continued growth 
and recovery. Because the 3H-epibatidine displacement 
assay (below) can be used with K4 callus growth media, 
recovery and growth of the microcalli within the wells is 
virtually 100%. Additional media is added to each well to 
increase the volume to 1.0 ml. 0.65 ml of the 1.0 ml volume 
of cellular ?uid resulting from the partial callus maceration 
in each well is removed and transferred to standard 1.5 ml 
micro-centrifuge tubes. After sealing the lids of the 48-well 
dishes with surgical tape (3 M), they are placed in a lighted 
26° C. incubator for recovery and growth. The growing calli 
within the 48-well dishes establishes the working library. 
Example 5 
Extract Preparation 
Micro-centrifuge tubes containing 0.65 ml of cell tissue 
?uid and K4 growth media are centrifuged at 13,000 rpm for 
ten minutes at room temperature. The supernatant is 
removed and placed into clean micro-centrifuge tubes and 
stored at —80° C. until used for displacement assays. 
Example 6 
[3H]-Epibatidine Screening 
Tissue Preparation: Crude membrane preparations from 
brains of male adult Sprague-Dawley rats were prepared 
from methods modi?ed after Houghtling R A, Davila-Garcia 
M I, Kellar K J, Mol Pharmacol 48(2):280—7, 1995, which 
reference is incorporated by reference herein in its entirety. 
Following sacri?ce by rapid decapitation, the frontal cortex 
and hippocampus were rapidly dissected and homogeniZed 
in ice-cold sucrose buffer (0.32 M sucrose, 1 mM EDTA, 0.1 
mM phenylmethylsulfonyl ?uoride, 0.01% wt/vol sodium 
aZide; pH adjusted to 7.4) using a polytron tissue homog 
eniZer. The homogenate was centrifuged at 1000><g at 4° C. 
for 10 min. The pellet was resuspended in sucrose buffer and 
the centrifugation repeated. The supernatant fractions were 
combined and the P2 membranes recovered as a pellet after 
centrifugation 15000><g at 4° C. for 20 min. The pellet was 
washed twice by resuspension in phosphate buffer (same as 
above, except 50 mM phosphate substituted for sucrose) and 
centrifuged at 15000><g at 4° C. for 20 min. The ?nal pellet 
was resuspended in phosphate buffer. Protein was deter 
mined by the BCA Protein AssayTM kit from Pierce, Rock 
ford Ill. Aliquots were stored at —80° C. until use. 
Preparation of membrane homogenates: Fresh tissue (bo 
vine brain) was procured immediately after euthanasia by 
exsanguination. Alternatively, standards and replication of 
results were con?rmed in male Sprague-Dawley rat cere 
brum homogenates derived from animals sacri?ced by rapid 
decapitation. The preparation of these membranes was iden 
tical to bovine homogenates. Frontal cortex was blocked, 
then placed in ice-cold HEPES buffer (50 mM) for 10 min. 
Tissue was weighed, and 4 ml of “incubation” buffer was 
added. Tissue was homogeniZed in a 30 ml vol. glass 
hand-held tissue homogeniZer with a te?on pestle. The crude 
homogenate was washed 3 times by centrifugation at 
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35,000><G for 20 min at 4° C. After each centrifugation, the 
homogenate was re-suspended in fresh, cold buffer. Follow 
ing ?nal washing, 1 ml aliquots were snap-froZen in liquid 
nitrogen and stored in a —20° C. freeZer until use. Prior to use 
in binding assays, total protein concentration was deter 
mined using a modi?ed Lowry method (Sigma Kit) for 
membrane bound proteins. Protein concentration effects and 
protein loss were investigated by preparing aliquots of 
known dilutions of membrane protein suspension into wells, 
?ltering, and measuring the protein concentration remaining 
on the plate ?lters via the Lowry method. 
Competition binding: To reduce binding of radiolabel to 
?lters, 0.1% BSA was added to the assay buffer. Membranes 
were diluted with buffer to yield a ?nal protein concentration 
of 600 pig/well (2 mg/ml). Membranes were added to the 
wells of a 96-well microtiter plate and incubated at room 
temperature with 10 nM [3H]-MLA, and unlabelled ligand 
or unknown samples (100 pl each). Incubation was halted 
after 2 hr by the addition of ice-cold buffer. The contents of 
the microtiter plate were harvested onto a 96 well ?lterplate 
using a plate harvester (Packard, Inc). Filters were washed 
5>< with ice cold buffer and the ?lterplate dried overnight. 
Scintillation cocktail was then added to the ?lters and the 
entire plate counted using a TopCountTM 96-well plate 
scintillation counter, Packard Instruments, Meriden Conn. 
Procedures for 3H-epibatidine binding in 96-well ?lter 
plates: All procedures were performed at room temperature, 
unless noted. Assays were performed in standard (350 pl 
well volume) 96 well microtiter plates. Nicotine or a sample 
competitor was added to 8 wells at a time using an 8-channel 
multipipettor. Crude sample extracts were solubiliZed using 
1N HCl, if necessary. Unknown samples were diluted with 
incubation buffer (50 mM Tris-HCl, 120 mM NaCl, 5 mM 
KCl, 1 mM MgCl2, 2 mM CaCl2, pH adjusted to 7.4) 1:10. 
This dilution allows an approximate weight:volume ratio of 
100 mg/ml of unknown sample per well. 100 pl of a 
competitor was added to each respective well. Non speci?c 
binding for epibatidine was determined using 10 mM nico 
tine competition. Membrane homogenates were thawed on 
ice and diluted with incubation buffer for ?nal protein 
concentration of each well equal to 4 mg/ml. Membrane 
homogenate preparation was added to 8 wells at a time, 
using 8-channel pipettor. A competitor was incubated within 
wells for 1 hr. at room temp. Following incubation of 
competitor, 3H-epibatidine (New England Nuclear) was 
added to each well and incubated for 2 hr. Following 
incubation, the plate was harvested onto a 96 well GF/B 
?lter plate using a Packard 96 well harvester, and rapidly 
washed 3x with 350 pl 50 mM Tris-HCl buffer (pH=7.4). 
The plate was then allowed to dry overnight, then 30 pl 
MicroScint20TM was added to each well before counting 
with a Packard TopcountTM 96-well plate scintillation 
counter. Each well was counted for 2 min. Speci?c binding 
in the presence of competitor was converted to percentage of 
total speci?c binding of 3H-epibatidine alone. Signi?cant 
differences were calculated from CPM averages using Stu 
dent’s 2 tailed t tests. 
Example 7 
Results 
Screening of Activation-Tagged Microcalli: 4400 activa 
tion tagged microcalli were screened in a six month period. 
This was a 75% increase in ef?ciency over previous meth 
odologies. 
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Identi?cation of Microcalli with Signi?cant Alkaloid 
Displacing Activity: Two stable cell lines were identi?ed 
that showed signi?cant alkaloid-displacing activity. One of 
these, 1402, was examined at the whole plant level and 
showed a 7.5-fold increase in the level of displacement 
activity over the wild type in extracts prepared from leaf 
punches from nontransformed plants. The second identi?ed 
isolate, 5094, showed displacement activity in callus tissue 
extracts equivalent to alkaloid levels of several orders of 
magnitude over the wild-type calli. 
Example 8 
Isolation and Replication of Activated Genes 
Isolation: Molecular genetic techniques are conducted 
using standard methodologies. The analytical sequence is 
determined by isolating the plant genomic DNA activated by 
the T-DNA insert through Southern hybridiZation analysis, 
followed by polymerase chain reaction (PCR) to establish 
the insert number and structure. Cloning of the T-DNA along 
with ?anking genomic plant DNA will depend on the 
structure of the insert, ?rst utiliZing plasmid rescue for single 
site T-DNA insertions. If there are multiple inserts, then 
genomic libraries will be prepared and screens conducted on 
these to obtain genomic clones linked to the T-DNA that 
contain different plant genomic DNA sequences. Resulting 
clones can be sorted ?rst by Southern analysis and then 
functionally by reintroduction into wild-type protoplasts and 
scoring microcalli for the original phenotype. If necessary, 
subclones of the recovered ?anking plant DNA can be 
prepared and tested for activity by fusing various fragments 
downstream of the 35S promoter of the Cauli?ower mosaic 
virus, introducing these back into protoplasts and scoring 
these cells for the phenotype. Once the putative activated 
genomic DNA is identi?ed, it is used as a probe to screen 
cDNA libraries of tobacco. In addition, functional analysis 
to determine nicotinic alkaloid pathway upregulation can be 
performed by reverse transcription PCR using oligonucle 
otide primer speci?c to the pmt gene of tobacco. This 
provides early molecular evidence if the alkaloid pathway 
was induced in callus tissue, for example. 
Example 9 
We have prepared extracts from about 8000 clonal cul 
tures and have screened these for [3H] epibatidine-displacing 
activity. Approximately 12 of these produced activity that 
met the criteria of being “positive” in the ?rst screen. Of 
these, only three have met the criteria that daughter cultures 
should continue to overproduce activity in the screen 
through several cycles of growth and separation. The extent 
of the increase in activity varies markedly between these 
three clones. Thus, the ?rst clone isolated (#1402) producing 
a compound or compounds with a biological activity in the 
screen equivalent to a concentration of nicotine an order of 
magnitude higher than that produced by wild-type cultures 
(see FIG. 8). A very recent clone (#7309) is producing 
activity about 10,000>< that of wild-type whereas the other 
clone (#5094) is intermediate between these (FIG. 8). 
Because we isolated #1402 ?rst we have spent most time 
characteriZing this clone, and the speci?c ?ndings will be 
described below. 
The results show that ATM can be used to create a large 
library of mutant clonal cultures (see FIG. 4) that can be 
maintained by a small number of research workers. We have 
also shown that clones in this library can be repeatedly 
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sampled and separated Without destroying the individual 
cultures. Extracts from these cultures can therefore be 
sampled and screened serially to evaluate Whether the 
genetically produced chemical phenotype is stable. We have 
also shoWn that it is possible to adapt pharmacological HTS 
techniques to evaluation of a clonal library produced by 
ATM, and that the amplitude of changes in secondary 
metabolites from Wild-type or other control cultures that are 
produced by ATM can be detected by this HTS. We are thus 
able to combine ATM and HTS—the ?rst requirement for 
proof of the Natural Products Genomics concept. Our results 
using this combination of techniques shoW that a small 
number of clones (currently around 1 in 2,700 mutants) can 
be regarded as stable alterations in genes that increase the 
synthesis of products With a biological activity similar to 
nicotine. These products may be nicotine itself, or some 
other chemical With activity in the screen, at this stage We do 
not knoW. Similarly, the genes that have been activated may 
have an impact on the nicotine metabolic pathWay, or be 
completely unrelated to this. All We knoW is that they 
increase the production of natural compounds With poten 
tially useful biological activity that is similar to that of 
nicotine. In fact, We may Well be underestimating the 
numbers of clones that have this type of value. About 75% 
of the clones that give a positive result in the ?rst screen 
eventually fail, sometimes after several generations of posi 
tive daughter cultures. Some cultures even recover activity 
after producing negative data for a While. In some cases, this 
may indicate that We have activated a gene that regulates the 
production of the natural product very indirectly, and that its 
effects can be over-ridden by other genes that may be 
activated by environmental or developmental factors beyond 
our control. HoWever, such genes might still be useful as a 
means of regulating synthesis of the natural product. We 
have been deliberately conservative in our criteria to avoid 
the criticisms previously associated With unstable somatic 
mutations in plant cell culture. Considered together We 
believe that our results demonstrate that ATM and HTS have 
the potential to act as a discovery platform for those genes 
that regulate the synthesis of natural products in plants. As 
our characteriZation of clone 1402 has shoWn (see beloW) 
this Natural Products Genomics approach has utility as a 
drug discovery platform technology. 
Clone 1402 has noW consistently over-produced activity 
in the epibatidine displacement screen for about 18 months. 
This has been in various incarnations of the original clonal 
material that originated from a single protoplast subjected to 
ATM (see FIG. 8). Thus, daughter cultures of the original 
clone continued to overproduce activity in the screen. Some 
of these cultures Were regenerated into intact plants Which 
set seed. Extracts of the seed Were screened, and these 
continued to shoW greater activity in the screen than Wild 
type N tabacum seed. Plants Were groWn from this seed and 
leaf punch extracts from young seedlings shoWed greater 
activity in the screen than leaf punches from Wild-type 
seedlings. Leaf protoplasts from these plants Were groWn to 
the microcallus level and these microcalli Were found to be 
still overproducing activity relative to Wild-type cultures. 
The only situation in Which clone 1402 Was not found to 
be an overproducer relative to Wild-type Was in leaf punches 
from relatively mature plants. At this stage nicotine produc 
tion is rising rapidly in the Wild-type plants and this might 
Well eliminate the difference from the clonal plant. Addi 
tionally, assessing the production of nicotine-like alkaloids 
in leaf punches from mature plants is subject to the Heisen 
berg principle because leaf damage massively increases the 
synthesis and transport of nicotine. Our failure to observe a 
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difference in the screen betWeen clone 1402 and Wild-type 
plants at the mature plant stage illustrates the potential 
dif?culties of evaluating differences in natural products in a 
population of mutant intact plants. Metabolic pro?ling of the 
plants at this stage by GC/MS also did not reveal any 
differences in alkaloid material (see FIG. 7). 
Since 1402 consistently overproduces activity in the epi 
batidine displacement screen it Would seem to be a simple 
matter to establish What compound or compounds it is 
producing that account for this activity. Unfortunately this is 
more dif?cult than Would be expected. The problem is one 
of sensitivity and quantitation. The screen is semi-quantita 
tive at best, but it is extraordinarily sensitive, being easily 
able to respond to picogram quantities of nicotine in a 
culture extract. Chemical analytical methods such as 
GC/MS (as in FIG. 7) are about 1000>< less sensitive, and to 
date We have not accumulated enough clonal culture mate 
rial to be able to analyZe extracts quantitatively for knoWn 
and novel nicotine-like alkaloids. We have therefore used a 
combination of pharmacological analysis and separation 
techniques to investigate extracts of clone 1402 in compari 
son With extracts from Wild-type microcallus. 
Nicotine is the most pharmacologically alkaloid in the 
intact plant, and this alkaloid can be detected by GC/MS in 
extracts from Wild-type cultures. Therefore, the most likely 
reason for the increased activity in extracts from clonal 
culture #1402 is that this is producing more nicotine than the 
Wild-type cultures. This does not appear to be the case. Thus, 
this clonal culture Was identi?ed on the basis of greater 
displacement of epibatidine, a ligand With relative selectiv 
ity for alpha3-containing nicAChRs on brain membranes. In 
contrast, nicotine, and the partial agonist cytisine, have a 
higher af?nity for nicAChRs on brain containing alpha4 
subunits. If the active principle in clone #1402 is nicotine it 
should displace [3H]nicotine or [3H]cytisine from brain 
membranes to a greater extent than it displaces [3H]epiba 
tidine. In fact the reverse is the case—the same extract from 
1402 that is an order of magnitude more effective at dis 
placing epibatidine is no more effective than that from 
Wild-type cultures in displacing nicotine or (see FIG. 9). 
This suggests that Whatever is responsible for the activity 
has a greater af?nity for alpha3-containing nicAChRs, and 
this is inconsistent With this being nicotine or probably any 
of the other major alkaloids in tobacco (see beloW). 
FIG. 9 also shoWs another important pharmacological 
characteristic of the culture extracts. The dilution/response 
relation in the screens is very similar to that for pure 
nicotine. This suggests that the displacement of the respec 
tive radioligands is by direct competition for the binding 
site, rather than by indirect or allosteric effects. This type of 
interaction suggests an alkaloid that is a structural relative of 
nicotine rather than a totally different type of compound. For 
example We knoW that the cultures produce polyamines (see 
beloW) and these compounds can affect nicAChR binding 
allosterically. The suggestion that the compound in clone 
1402 is structurally similar to the knoWn tobacco alkaloids 
is supported by results from serial fractionation of the 
extracts from #1402 and Wild-type cultures. We compared 
these fractions for activity in the radioligand binding screens 
and also compared the recovery in each phase With that of 
standards representing the major alkaloids present in N 
tabacum. In general, the activity in extracts from #1402 
shoWed a similar distribution to that from Wild-type cultures 
and to that of alkaloid standards (not shoWn here). 
Taken together, all this data is consistent With the pro 
duction, by clone 1402, of an alkaloidal compound (or 
compounds) With structural similarity to nicotine, but Which 
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bind With high af?nity to nicAChs containing alpha3 sub 
units. Since none of the major alkaloids in the plant have 
exactly these characteristics, then We appear to have pro 
duced a stable mutation that causes “overproduction” either 
of a compound that is not normally found in the plant, or one 
that is normally produced in very small amounts. This 
?nding, and the procedure We used to come to this conclu 
sion, has some implications for drug discovery. Speci?cally, 
if the main purpose of this technology is to discover clones 
that are producing active compounds other than the major 
active principle in the plant, it is a simple matter to use 
differential activity in tWo related screens to do this. Those 
clones that are simply overproducing the “Wild-type com 
pound” Will produce a characteristic ratio of activity in the 
tWo screens. Those that are producing some product With 
novel properties Will usually produce a ratio of activity that 
differs from this. 
Since the T-DNA that has been inserted into the N 
tabacum genome during the ATM procedure is “tagged” 
With bacterial DNA, it is a relatively simple method to 
rescue this material together With sections of the plant genes 
surrounding it. HoWever, this does not guarantee that the 
piece of plant DNA that is obtained is responsible for the 
altered chemical phenotype. Thus the in?uence of the viral 
enhancer sequences inserted into the genome extends for as 
much as 10-Kb pairs in each direction from the insert, and 
it may be any gene Within this range that is of value for 
natural product synthesis. Another potential problem is that 
there may be more than one insert. The important activation 
may be in one of these rather than the other or, possibly, it 
could require both. Fortunately clone #1402 has only one 
T-DNA insert and We have used plasmid rescue techniques 
to obtain genomic plant DNA from the region of this insert. 
To date We have isolated approximately 1.8-Kb pairs of this 
material (see FIG. 10), Which is probably of insuf?cient 
length to encode a complete gene. HoWever, the sequence 
analysis indicates very strongly suggests that the cloned 
genomic DNA does indeed encode intact genes in that the 
deduced amino acid sequence from this region reveals some 
homology With expressed genes When compared With exist 
ing gene databanks. In particular, there is homology With 
expressed sequence tags obtained from a soybean roots that 
represents a gene of unknown function (FIG. 10). Since the 
nicotine alkaloids are synthesiZed in roots, this at least 
shoWs the expected tissue speci?city. 
Those skilled in the art Will recogniZe, or be able to 
ascertain using no more than routine experimentation, many 
equivalents to the speci?c embodiments of the invention 
speci?cally described herein. Such equivalents are intended 
to be encompassed in the scope of the folloWing claims. 
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We claim: 
1. A method for identifying plant genetic material Whose 
actions cause increased production of a metabolite or 
metabolites of interest in plant cells, said method compris 
ing: 
a) causing random integration into the plant genome in 
plant protoplasts of at least one enhancer-containing 
T-DNA genetic element harboring sequences to enable 
bacterial replication and selection; 
b) groWing said protoplasts to the stage of callus cultures; 
c) sampling said callus cultures in such a manner as to 
retain viability thereof and to obtain cells for continued 
groWth and recovery, 
d) analyZing said cells by at least one radioligand dis 
placement assay to identify the callus cultures produc 
ing the metabolite or metabolites of interest, Wherein 
the radioligand is a nicotine acetylcholine receptor 
antagonist or a nicotine acetylcholine receptor agonist; 
and 
e) isolating and identifying the plant genetic material, the 
action of Which has been stimulated by the enhancer 
containing T-DNA genetic element in the sampled, 
identi?ed callus cultures. 
2. Amethod of claim 1, Wherein the plant genetic material 
Which is identi?ed is a plant gene Whose action causes a 
plant cell to produce an increased amount of a metabolite or 
metabolites of interest. 
3. Amethod of claim 2, Wherein the plant genetic material 
Which is identi?ed is a regulatory gene. 
4. A method of claim 1, Wherein the analysis of callus 
cultures detects the production of metabolites of interest 
having pharmacological properties. 
5. A method of claim 1, Which comprises the further step 
of propagating at least one callus culture producing said 
metabolite or metabolites. 
6. A method of claim 1, Wherein said plant is a tobacco 
plant. 
7. A method of claim 1, Wherein said enhancer sequence 
is a plant viral enhancer sequence. 
8. A method of claim 7, Wherein said enhancer sequence 
is delivered to the plant via Agrobacterium tumefaciens. 
9. A method of claim 1 Wherein said radioligand is a 
nicotinic acetylcholine receptor agonist. 
10. A method of claim 1, Wherein said radioligand is a 
nicotinic acetylcholine receptor antagonist. 
11. A method of claim 1, Wherein said radioligand is 
3H-epibatidine. 
12. A method of claim 1, Wherein said radioligand is 
3H-methyllycaconitine. 
* * * * * 
